Healthcare includes businesses with very different economics—from profitable providers and device makers to development-stage biotechnology companies. This list ranks the healthcare theme with Wall Street Score so users can compare the broader quality and valuation picture.
Educational research only—not investment advice, a recommendation, or a prediction of future performance. Rankings can change as prices, filings and company data are refreshed. Verify important information independently.
Coverage: qualifying stocks with market capitalization of at least $10 billion, complete scoring inputs, and a financial refresh within 240 days. This is a limited research universe, not a ranking of every listed company. A refresh date is not the financial reporting period. Revenue CAGR measures annualized historical growth, not a forecast. Check dividend history for the yield basis and any special payments.
Click any company to open its full stock research page.
| Rank | Company | WSS | Price | Revenue CAGR |
|---|---|---|---|---|
| #1 | Universal Health Services, Inc. UHS · Healthcare | 72 | $186.89 | 10.3% |
| #2 | Cigna Corporation CI · Healthcare | 71 | $295.81 | 18.7% |
| #3 | Incyte Corporation INCY · Healthcare | 66 | $116.62 | 17.9% |
| #4 | BeOne Medicines AG ONC · Healthcare | 66 | $366.06 | 47.4% |
| #5 | Neurocrine Biosciences, Inc. NBIX · Healthcare | 66 | $144.79 | 23.1% |
| #6 | Exelixis, Inc. EXEL · Healthcare | 64 | $64.58 | 12.6% |
| #7 | Globus Medical, Inc. GMED · Healthcare | 64 | $81.41 | 36.9% |
| #8 | argenx SE ARGX · Healthcare | 63 | $869.72 | 84.0% |
| #9 | Smith & Nephew plc SNN · Healthcare | 60 | $30.83 | 5.4% |
| #10 | Insulet Corp. PODD · Healthcare | 58 | $149.83 | 26.3% |
| #11 | Zoetis Inc. ZTS · Healthcare | 58 | $77.8 | 5.3% |
| #12 | Boston Scientific Corporation BSX · Healthcare | 57 | $45.06 | 18.7% |
| #13 | United Therapeutics Corporation UTHR · Healthcare | 57 | $586.49 | 16.9% |
| #14 | Tenet Healthcare Corporation THC · Healthcare | 57 | $269.07 | 1.8% |
| #15 | McKesson Corporation MCK · Healthcare | 55 | $960.56 | 14.3% |
| #16 | ResMed Inc. RMD · Healthcare | 55 | $246.69 | 9.8% |
| #17 | Encompass Health Corporation EHC · Healthcare | 54 | $124.1 | 11.2% |
| #18 | Regeneron Pharmaceuticals, Inc. REGN · Healthcare | 54 | $805.02 | 4.6% |
| #19 | DexCom, Inc. DXCM · Healthcare | 52 | $85.74 | 13.4% |
| #20 | Medpace Holdings, Inc. MEDP · Healthcare | 51 | $673.79 | 15.8% |
| #21 | The Ensign Group, Inc. ENSG · Healthcare | 51 | $177.07 | 16.5% |
| #22 | UnitedHealth Group Incorporated UNH · Healthcare | 50 | $410.39 | 9.7% |
| #23 | Omega Healthcare Investors, Inc. OHI · Real Estate | 50 | $46.13 | 12.3% |
| #24 | HCA Healthcare, Inc. HCA · Healthcare | 50 | $469.03 | 7.9% |
| #25 | Elevance Health Inc. ELV · Healthcare | 47 | $414.41 | 7.8% |
We select securities classified in the healthcare theme, require a current Wall Street Score, exclude ranking-ineligible securities and sort the remainder by WSS.
Because this page reads from the same stock database used by Wall Street Score, it does not need a manually rewritten ranking every day. Changes in the underlying data can change which stocks qualify and their order.
Treat the list as a starting point for research. Open individual stock pages to review the underlying score components, valuation and intrinsic value, financial health, corporate-risk warnings, insider activity and other available signals before reaching your own conclusion.
Read the Wall Street Score methodologyIdentify whether revenue comes from marketed treatments, devices, services or another activity. Development-stage biotechnology should not be compared mechanically with an established provider. For drug developers, read trial stage, endpoints, enrollment, regulatory status and cash runway. A pipeline announcement does not establish future approval or sales.
Review dependence on a single drug, patent, customer or reimbursement arrangement. A company can report strong historical margins while facing a patent expiry or a costly launch. Compare cash use with available funding and potential dilution. This industry screen does not evaluate clinical evidence or replace company and regulator disclosures.
Healthcare can include providers, insurers, medical-device companies, pharmaceutical businesses and biotechnology firms, each with different risk profiles.
Earnings, trial results, regulatory decisions, reimbursement changes and financing events can materially alter a healthcare company's risk and valuation.
Best Dividend Stocks Ranked by Wall Street Score
View current rankings
AI-Related Industry Screen by Wall Street Score
View current rankings
Best Semiconductor Stocks Ranked by Wall Street Score
View current rankings
Best Value Stocks Ranked by Valuation and Wall Street Score
View current rankings
Stocks Ranked by Insider Activity Score
View current rankings
Stocks at $10 or Less Ranked by Wall Street Score
View current rankings
Highest Available Wall Street Scores
View current rankings
Top REITs Ranked by Wall Street Score
View current rankings
Best Growth Stocks Ranked by Growth and Wall Street Score
View current rankings